[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612894":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":27,"locations":33,"responsibleParty":49,"collaborators":26,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":26,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":26,"enrollmentInfo":62,"targetDuration":26,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":36,"whyStopped":26,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Universitas Sebelas Maret","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Once-Daily Ramipril","EXPERIMENTAL","Participants receive ramipril 10 mg once daily for 30 days",[13],"Drug: Ramipril",{"label":15,"type":10,"description":16,"interventionNames":17},"Twice-Daily Ramipril","Participants receive ramipril 5 mg twice daily for 30 days",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Ramipril","Ramipril administered either as 10 mg once daily or 5 mg twice daily for 30 days",[9,15],[25],"ACE inhibitor",null,[28],{"name":29,"role":30,"phone":31,"phoneExt":26,"email":32},"Evi L Wulandari, MD., Internist","CONTACT","(+62)821-3587-2749","evililiek@staff.uns.ac.id",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":26,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"UNS Hospital","RECRUITING","Kartasura","Central Java","Indonesia","ID",{"type":42,"coordinates":43},"Point",[44,45],110.73778,-7.55194,{"lat":45,"lon":44},[48],{"name":29,"role":30,"phone":31,"phoneExt":26,"email":32},{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Evi Liliek Wulandari","Principal Investigator, Consultant Internist (Internal Medicine Specialist)","100612894","phase-4-single-and-twice-daily-dosing-of-ramipril-on-renal-function-in-chronic-kidney-disease-patients-with-reduced-ejection-fraction-heart-failure-100612894",false,"NCT07259512","Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure","Comparative Effects of Single Versus Twice-Daily Ramipril Dosing on Renal Function in Patients With Chronic Kidney Disease and Heart Failure With Reduced Ejection Fraction: Evaluation of Plasma Renin Activity, Malondialdehyde, Interleukin-6, Albuminuria, and Cystatin C","Inclusion Criteria:\n\n* Female or Male with age \\>18 years old\n* Patients with a diagnosis of CKD stage 3-5 non-dialysis with low ejection fraction heart failure (ejection fraction \\\u003C 40%)\n\nExclusion Criteria:\n\n* Receiving hemodialysis therapy\n* History of intolerance to ACE inhibitors\n* Refractory hyperkalemia\n* Pregnancy\n* History of angioedema to ACE inhibitors\n* Receiving sacubitril-valsartan therapy\n* Receiving ARB therapy\n* Hypotension with blood pressure \\\u003C90\u002F60, or patients in shock.","ALL","18 Years",{"count":63,"type":64},80,"ESTIMATED","INTERVENTIONAL",[67],"PHASE4","This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.",[70,71],"Chronic Kidney Disease","Heart Failure With Reduced Ejection Fraction (HFrEF)",[70,73,21],"HFrEF","2025-12-02",{"date":76,"type":77},"2025-12-10","ACTUAL",{"date":79,"type":77},"2025-06-30",{"date":81,"type":64},"2026-01-31",{"name":51,"class":6},1]